A PHASE II STUDY OF PRO143966 IN COMBINATION WITH Ro50-8231 AS A FIRST LINE THERAPY IN PATIENTS WITH MET-POSITIVE AND EGFR MUTATION POSITIVE NON-SMALL CELL LUNG CANCER (MATERIAL study)
Latest Information Update: 01 Feb 2018
At a glance
- Drugs Onartuzumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms MATERIAL
- Sponsors Chugai Pharmaceutical
- 07 Jun 2016 New trial record